Quarterly ResultMay 7, 2026, 07:12 AM
Korro Bio Raises $88.2M; Q1 Net Loss Narrows to $19.6M
AI Summary
Korro Bio reported a net loss of $19.6 million for Q1 2026, an improvement from $23.4 million in Q1 2025, while collaboration revenue dropped to zero. The company significantly bolstered its liquidity by raising $88.2 million through a private placement and an at-the-market equity program. This capital infusion increased cash, cash equivalents, and marketable securities to $157.1 million, extending its cash runway for at least 12 months, despite the ongoing accumulated deficit and a paused collaboration with Novo Nordisk.
Key Highlights
- Net loss for Q1 2026 was $19.6 million, an improvement from $23.4 million in Q1 2025.
- Collaboration revenue for Q1 2026 was $0, down from $2.55 million in Q1 2025.
- Raised $88.2 million in net cash from financing activities, including a private placement and ATM program.
- Cash, cash equivalents, and marketable securities totaled $157.1 million as of March 31, 2026.
- Net cash used in operating activities decreased to $16.1 million in Q1 2026 from $24.5 million in Q1 2025.
- Accumulated deficit reached $403.5 million as of March 31, 2026.
- Novo Nordisk collaboration is paused for 12 months as of November 2025.
Price Impact
More from KRRO